Groundbreaking Research at Space Station Transforms Cancer Treatment
Scientists have made a groundbreaking discovery that could revolutionize cancer treatment by harnessing the benefits of microgravity. Researchers working with Merck, a leading pharmaceutical company, have used NASA's International Space Station to develop a new formulation of the life-saving drug pembrolizumab.
The breakthrough was achieved through protein crystal growth research, which yielded early insights into the structure and size of particles best suited for the development of the cancer medicine. The new subcutaneous injectable form offers a significant time-saving alternative to intravenous infusion, with treatment times reduced from up to two hours to just one minute every three weeks.
Merck has been working with NASA since 2014 to study how crystals form in space, including the monoclonal antibody used in this cancer treatment. By growing larger, more uniform crystals in microgravity, scientists were able to produce crystalline suspensions that dissolve easily in liquid, making it possible to deliver medication by injection.
The research conducted at the space station has provided valuable insights into how gravity influences crystallization, helping to improve drug formulations and advance medical development. The findings have significant implications for patients on Earth, who will benefit from reduced treatment times and improved quality of life.
NASA's collaboration with private industry has not only expanded access to cutting-edge research but also paved the way for human exploration of the Moon and Mars. As scientists continue to push the boundaries of space-based research, they are making a tangible impact on lives here on Earth.
Scientists have made a groundbreaking discovery that could revolutionize cancer treatment by harnessing the benefits of microgravity. Researchers working with Merck, a leading pharmaceutical company, have used NASA's International Space Station to develop a new formulation of the life-saving drug pembrolizumab.
The breakthrough was achieved through protein crystal growth research, which yielded early insights into the structure and size of particles best suited for the development of the cancer medicine. The new subcutaneous injectable form offers a significant time-saving alternative to intravenous infusion, with treatment times reduced from up to two hours to just one minute every three weeks.
Merck has been working with NASA since 2014 to study how crystals form in space, including the monoclonal antibody used in this cancer treatment. By growing larger, more uniform crystals in microgravity, scientists were able to produce crystalline suspensions that dissolve easily in liquid, making it possible to deliver medication by injection.
The research conducted at the space station has provided valuable insights into how gravity influences crystallization, helping to improve drug formulations and advance medical development. The findings have significant implications for patients on Earth, who will benefit from reduced treatment times and improved quality of life.
NASA's collaboration with private industry has not only expanded access to cutting-edge research but also paved the way for human exploration of the Moon and Mars. As scientists continue to push the boundaries of space-based research, they are making a tangible impact on lives here on Earth.